CBP-1018
Prostate Cancer (mCRPC)
Phase 1/2Active
Key Facts
About Coherent Biopharma
A clinical-stage biotech company developing bi-targeting XDC drugs to treat cancer and address undruggable targets.
View full company profileTherapeutic Areas
Other Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ZEN-3694 | Zenith Epigenetics | Phase 2 |
| TLX591 (177Lu-DOTA-rosopatamab) | Telix Pharmaceuticals | Phase 3 |